TB-500 Dosage: What People Use (and What's Actually Unknown)

Search "TB-500 dosage" and the internet answers with reassuring precision: a "loading phase" of around 2 to 2.5 mg injected twice a week for four to six weeks, then a lower "maintenance" dose every week or two. It reads like a protocol lifted from a prescribing label. It isn't. There is no established, FDA-validated human dose for TB-500, because there is no FDA-approved TB-500 product and no human dosing trial has ever been completed. Every number circulating online is an extrapolation — from animal studies of thymosin β4, from one vendor copying another, or from nothing at all. This article lays out where those numbers come from, why they can't be trusted, and the wide gap between "a dose people use" and "a dose shown safe and effective in humans."

We are not going to hand you a protocol. This is not medical advice, TB-500 is an unapproved research chemical, it is banned in tested sport, and the dosing question is genuinely unanswered. What follows is the honest version of what's actually known.

The Honest Headline: No Validated Human Dose Exists

Start with the single fact everything else depends on. The published science is on thymosin β4 (Tβ4) — a naturally occurring 43-amino-acid protein whose best-characterized job is binding and sequestering actin, the building block cells use to remodel their internal skeleton¹. "TB-500" is the research-chemical market's name for a synthetic peptide sold as thymosin β4 (often described as an active fragment). The distinction matters for dosing: there is no dose-finding study telling you how much TB-500 a person should inject, how often, or where the safety ceiling sits — and anti-doping science reviewers note plainly that no peer-reviewed studies have investigated the clinical safety of TB-500 specifically⁵.

So when a vendor or forum gives you "the standard TB-500 protocol," understand what that phrase hides. There is no standard. There is no human study establishing what works or what's safe. The confident numbers are borrowed — and the well they're borrowed from is the animal literature.

Where the Common Numbers Actually Come From

Thymosin β4's animal and cell studies do use defined doses, and this is where most online protocols originate. In rodent models of tissue repair — a rat study of medial collateral ligament healing, for example² — the peptide is dosed by body weight and delivered by injection into lab animals, not people. A rat is not a human, and a dose that nudges a rat ligament toward faster healing tells you nothing reliable about what a human needs, tolerates, or should avoid.

Here is where the extrapolation goes wrong in a specific, checkable way. The popular "2 to 2.5 mg twice a week" figure is not derived from any human study; it appears to be community folklore that drifted into vendor copy and then hardened into a "standard." Even the loading-then-maintenance structure — a big front-loaded dose, then a smaller upkeep dose — is borrowed from how other injectables are run, not from any measured TB-500 exposure-response curve in humans. Neither the numbers nor the schedule is anchored to human data, because no human dose-finding study exists³⁵.

Why the Missing Pharmacokinetics Make "A Dose" Hard to Even Define

To pick a rational dose and dosing frequency, you need to know how long the compound circulates and how much of an injected amount actually reaches the bloodstream — its pharmacokinetics. For TB-500, there is no published human pharmacokinetic study at all. The "twice weekly" spacing that anchors every protocol is therefore an assumption, not a finding: nobody has measured how long injected TB-500 persists in a person or how that maps to any effect. You cannot rationally choose a dose and interval for a drug whose human exposure-response relationship has never been measured.

This is worth pausing on, because the loading/maintenance framing implies a level of pharmacological knowledge that simply doesn't exist for TB-500. A "maintenance dose" is a concept that only means something once you know the compound's half-life and the exposure needed to sustain an effect. For TB-500 in humans, both are unknown.

The "Local vs Systemic" Injection Question Is Also Unsettled

TB-500 is usually pitched as a systemic peptide — inject it anywhere and thymosin β4's cell-migration and angiogenic signaling travels to wherever repair is needed — in contrast to BPC-157, which forum protocols tell you to "pin near the injury." That systemic framing has a genuine mechanistic basis, since Tβ4 is present throughout the body and its actin-handling role is a general cellular function¹⁴. But "mechanistically plausible that it acts body-wide" is not the same as "here is the correct injected dose and site in a human." No controlled human study has compared injection sites, routes, or systemic-versus-local dosing for TB-500. The site and route conventions you'll read are convention, not evidence. We compare the two peptides' mechanisms and marketing head-to-head in BPC-157 vs TB-500, and the popular pairing in the BPC-157 + TB-500 stack review.

The Only Human Data Doesn't Tell You How to Dose the Injectable

Being honest means acknowledging that some human thymosin β4 data exists — and then being precise about what it does and doesn't establish. A European prospective randomized study tested topical thymosin β4 for venous (leg) ulcers, reporting it was safe, well tolerated, and healing-enhancing³, and the dermal-healing literature describes Tβ4's progression from animal models into wound-care patients⁶. That is real human data — but it is topical, applied to chronic skin ulcers, in patients under clinical supervision. It does not establish an injected dose for a healthy athlete chasing faster recovery. A dose validated for a gel on a leg ulcer is not a dose validated for a subcutaneous injection aimed at a torn tendon. The fuller evidence picture is in our TB-500 recovery evidence review.

The Vial Problem: You Can't Dose What You Can't Verify

Even if a "correct" TB-500 dose existed, there is a mechanical obstacle to hitting it: you cannot verify what's in the vial. Because no approved, quality-controlled TB-500 product exists, virtually all of it is sold "for research use only" by grey-market vendors, and anti-doping testing groups warn that unregulated peptide manufacturing can introduce contaminants including endotoxins, microbial contamination, and heavy metals⁵. Independent testing of grey-market peptides repeatedly finds identity, purity, and content inconsistencies — so the actual amount of peptide in a "5 mg" or "10 mg" vial is unknown. A person meticulously measuring out "2 mg" may be drawing up something quite different. Precise dosing of an imprecise product is a false comfort — which is why we walk through how to verify a peptide's COA and third-party testing and the vendor red flags that signal a bad vial. (The dose arithmetic also assumes you mixed the vial to a known concentration — that math is in how to reconstitute peptides.)

The Two Facts That Sit Above Any Dose

Before anyone reasons about milligrams, two non-negotiable facts apply at every dose.

It is banned in tested sport at any dose. Thymosin β4 / TB-500 has been on the World Anti-Doping Agency Prohibited List for over a decade, prohibited at all times — in and out of competition — and athletes have received multi-year sanctions for it⁵. For a drug-tested competitor, a positive test is a violation regardless of how small the dose. We cover the wider anti-doping picture in the WADA 2026 prohibited list for peptides and our guide to whether these peptides are safe and legal for athletes.

It is not an approved drug. TB-500 is not FDA-approved for any human use, and in 2023 the FDA classified it as a bulk drug substance that may present significant safety risks, effectively keeping it off the list pharmacies may legally compound for humans⁵. There is no approved finished product to dose.

Bottom Line

The honest answer to "what is the TB-500 dosage?" is: nobody knows, because it has never been established in a human trial. The "2 to 2.5 mg twice weekly, loading then maintenance" protocol you'll see quoted is folklore — extrapolated from animal studies of thymosin β4 and copied between vendors, untethered from any human dose-finding or pharmacokinetic research. There isn't even a published human half-life to justify the injection spacing every protocol assumes. The only human data is for a topical gel on skin ulcers, not an injected dose for athletic recovery.

Layer on top of that an unverifiable grey-market supply, an FDA bulk-substance flag, and a blanket WADA ban, and the dosing conversation collapses into a simpler one: this is an unproven, unapproved, banned peptide with no human-established dose. The thymosin β4 science is a reason to run human trials, not a license to pick a number and inject it. For where TB-500 ranks against the rest of the field, see our evidence-ranked guide to the best peptides for recovery and healing and our roundup of vetted recovery peptide providers. And because no validated dose exists, there's certainly no validated cycle — we explain why the "weeks on, weeks off" rules are anecdotal in peptide cycling protocols.